Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Trevena in a research report on Thursday, November 14th.

Trevena Stock Down 11.3 %

TRVN opened at $1.49 on Monday. The firm has a market cap of $1.29 million, a price-to-earnings ratio of -0.03 and a beta of 1.08. Trevena has a 52 week low of $1.13 and a 52 week high of $14.75. The business’s 50 day moving average is $1.72 and its two-hundred day moving average is $2.46.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.